Biotie reports Parkinson's data for tozadenant
Biotie Therapies Corp. (HSE:BTH1V) said twice-daily oral tozadenant for 12 weeks met the primary endpoint of reducing mean daily "off" time in which patients experienced symptoms of their Parkinson's disease (PD) vs. placebo in a Phase IIb trial. Biotie said that tozadenant also met several secondary endpoints, including increasing "on" time in which patients were symptom free. The double-blind, international trial enrolled 420 patients whose levodopa treatment was insufficient to control PD symptoms until their next dose.
Biotie, which declined to provide details, said it plans to analyze the data with partner UCB Group (Euronext:UCB) and expects a decision from UCB regarding next steps in 1Q13. UCB has exclusive, worldwide rights to tozadenant from Biotie and is responsible for Phase III testing and commercialization. Biotie gained rights to the product through its acquisition of Synosia Therapeutics AG, which had rights from Roche (SIX:ROG; OTCQX:RHHBY). Tozadenant ( SYN115) is a selective adenosine A2A receptor (ADORA2A) antagonist. ...